Overview

A Study of LY2775240 in Healthy Participants

Status:
Completed
Trial end date:
2017-10-05
Target enrollment:
Participant gender:
Summary
This study is conducted to determine the side effects related to LY2775240 given orally to healthy participants. Blood tests will be done to check how much LY2775240 is absorbed into the bloodstream and how long the body takes to get rid of it. Each participant will enroll in either Part A or Part B of the study, which will last about 14 weeks and 8 weeks respectively, including screening.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Apremilast